Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240

Revolution Medicines

Revolution Medicines

RVMD

0.00

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ: RVMD) with a Buy and raises the price target from $236 to $240.